<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T08:27:55Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9494264" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9494264</identifier>
        <datestamp>2022-10-18</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Psychiatry</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Psychiatry</journal-id>
              <journal-title-group>
                <journal-title>JAMA Psychiatry</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">2168-622X</issn>
              <issn pub-type="epub">2168-6238</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9494264</article-id>
              <article-id pub-id-type="pmcid">PMC9494264</article-id>
              <article-id pub-id-type="pmc-uid">9494264</article-id>
              <article-id pub-id-type="pmid">36129719</article-id>
              <article-id pub-id-type="pmid">36129719</article-id>
              <article-id pub-id-type="doi">10.1001/jamapsychiatry.2022.2862</article-id>
              <article-id pub-id-type="publisher-id">yoi220060</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="domain" specific-use="print">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-first">
                  <subject>Online First</subject>
                </subj-group>
                <subj-group subj-group-type="allowCommenting">
                  <subject>Comments</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effectiveness of Standard Sequential Bilateral Repetitive Transcranial Magnetic Stimulation vs Bilateral Theta Burst Stimulation in Older Adults With Depression</article-title>
                <subtitle>The FOUR-D Randomized Noninferiority Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Repetitive Transcranial Magnetic Stimulation vs Theta Burst Stimulation in Older Adults With Depression</alt-title>
                <alt-title alt-title-type="running-head">Repetitive Transcranial Magnetic Stimulation vs Theta Burst Stimulation in Older Adults With Depression</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Blumberger</surname>
                    <given-names>Daniel M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi220060aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mulsant</surname>
                    <given-names>Benoit H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thorpe</surname>
                    <given-names>Kevin E.</given-names>
                  </name>
                  <degrees>MMath</degrees>
                  <xref rid="yoi220060aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="yoi220060aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>McClintock</surname>
                    <given-names>Shawn M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="yoi220060aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Konstantinou</surname>
                    <given-names>Gerasimos N.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi220060aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Hyewon H.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi220060aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Nestor</surname>
                    <given-names>Sean M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="yoi220060aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Noda</surname>
                    <given-names>Yoshihiro</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="yoi220060aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rajji</surname>
                    <given-names>Tarek K.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi220060aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <xref rid="yoi220060aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Trevizol</surname>
                    <given-names>Alisson P.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="yoi220060aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Vila-Rodriguez</surname>
                    <given-names>Fidel</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="yoi220060aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="yoi220060aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Daskalakis</surname>
                    <given-names>Zafiris J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="yoi220060aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Downar</surname>
                    <given-names>Jonathan</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="yoi220060aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="yoi220060aff1"><label>1</label>Temerty Centre for Therapeutic Brain Intervention, Campbell Family Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada</aff>
              <aff id="yoi220060aff2"><label>2</label>Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada</aff>
              <aff id="yoi220060aff3"><label>3</label>Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada</aff>
              <aff id="yoi220060aff4"><label>4</label>Applied Health Research Centre (AHRC), Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto, Ontario, Canada</aff>
              <aff id="yoi220060aff5"><label>5</label>Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas</aff>
              <aff id="yoi220060aff6"><label>6</label>Harquail Centre for Neuromodulation, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</aff>
              <aff id="yoi220060aff7"><label>7</label>Department of Neuropsychiatry, Faculty of Medicine, Keio University School of Medicine, Tokyo, Japan</aff>
              <aff id="yoi220060aff8"><label>8</label>Toronto Dementia Research Alliance, University of Toronto, Toronto, Ontario, Canada</aff>
              <aff id="yoi220060aff9"><label>9</label>Non-Invasive Neurostimulation Therapies (NINET) Laboratory, University of British Columbia Hospital, Vancouver, British Columbia, Canada</aff>
              <aff id="yoi220060aff10"><label>10</label>Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada</aff>
              <aff id="yoi220060aff11"><label>11</label>Department of Psychiatry, University of California, San Diego Health</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> July 29, 2022.</p>
                <p content-type="published-online"><bold>Published Online:</bold> September 21, 2022. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamapsychiatry.2022.2862</uri></p>
                <corresp id="yoi220060cor1"><bold>Corresponding Author:</bold> Daniel M. Blumberger, MD, 1025 Queen St W, Room B1-2107, Toronto, ON M6J 1H4, Canada (<email xlink:href="daniel.blumberger@camh.ca">daniel.blumberger@camh.ca</email>).</corresp>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2022 Blumberger DM et al. <italic>JAMA Psychiatry</italic>.</p>
                <p content-type="author-contributions"><bold>Author Contributions</bold>: Dr Blumberger had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Blumberger, Mulsant, Nestor, Noda, Daskalakis, Downar.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Blumberger, Mulsant, Thorpe, McClintock, Konstantinou, Lee, Noda, Rajji, Trevizol, Vila-Rodriguez, Downar.</p>
                <p><italic>Drafting of the manuscript:</italic> Blumberger, Lee, Noda, Trevizol, Vila-Rodriguez, Downar.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Blumberger, Mulsant, Thorpe, McClintock, Konstantinou, Nestor, Noda, Rajji, Trevizol, Vila-Rodriguez, Daskalakis, Downar.</p>
                <p><italic>Statistical analysis:</italic> Thorpe.</p>
                <p><italic>Obtained funding:</italic> Blumberger, Nestor, Rajji, Daskalakis, Downar.</p>
                <p><italic>Administrative, technical, or material support:</italic> Blumberger, Mulsant, McClintock, Konstantinou, Lee, Nestor, Noda, Rajji, Trevizol, Vila-Rodriguez, Downar.</p>
                <p><italic>Supervision:</italic> Blumberger, Downar.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures: </bold>Dr Blumberger reports grants from Canadian Institutes of Health Research (CIHR) and the Temerty family through the Centre for Addiction and Mental Health (CAMH) Foundation during the conduct of the study; nonfinancial support from Magventure (in-kind equipment support for investigator-initiated research); grants from Brainsway (principal investigator of an investigator-initiated study and site principal investigator for sponsored clinical trials), National Institutes of Health (NIH), Brain Canada Foundation, Campbell Family Research Institute, and Patient-Centered Outcomes Research Institute outside the submitted work; received medication supplies for an investigator-initiated trial from Indivior; and has participated in advisory boards for Janssen and Welcony. Dr Mulsant reports grants from CIHR during the conduct of the study; grants from Brain Canada, CAMH Foundation, CIHR, Patient-Centered Outcomes Research Institute, and US NIH; nonfinancial support from Capital Solution Design LLC and HAPPYneuron in the form of free software used in a study funded by the CAMH Foundation and Brain Canada, respectively, outside the submitted work; personal and research funding from the Labatt Family Chair in Biology of Depression in Late-Life Adults at the University of Toronto; has been an unpaid consultant to Myriad Neuroscience; and has received research support from Eli Lilly and Company and Pfizer (medications for an NIH-funded clinical trial). Dr McClintock has consulted for Pearson Assessment; received royalties from Guilford Press Book; grants from the National Institute of Mental Health during the conduct of the study; research support from the NIH; and honorarium as a teaching faculty member in the Duke University Transcranial Magnetic Stimulation Visiting Fellowship. Dr Nestor reports grants from CIHR; research salary support from Sunnybrook Foundation during the conduct of the study; research support from the Hurvitz Brain Sciences Program, Sunnybrook Health Sciences Centre, and Sunnybrook Foundation; and research funding from the Norris Scholar Award and the Labatt Family Network for Research in Depression, Department of Psychiatry, University of Toronto. Dr Noda received a grant in aid for scientific research from the Japan Society for the Promotion of Science; research grants from Japan Agency for Medical Research and Development; investigator-initiated clinical study grants from Teijin Pharma and Inter Reha Co; receives research grants from Japan Health Foundation, Meiji Yasuda Mental Health Foundation, Mitsui Life Social Welfare Foundation, Takeda Science Foundation, SENSHIN Medical Research Foundation, Health Science Center Foundation, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Taiju Life Social Welfare Foundation, and Daiichi Sankyo Scholarship Donation Program; speaker’s honoraria from Dainippon Sumitomo Pharma, Mochida Pharmaceutical Co, Yoshitomiyakuhin Corporation, Qol Co, Teijin Pharma, and Takeda Pharmaceuticals within the past 5 years; and equipment in-kind support for an investigator-initiated study from Magventure, Inter Reha Co, Brainbox, and Miyuki Giken Co. Dr Rajji has received research support from Brain Canada, Brain and Behavior Research Foundation, BrightFocus Foundation, Canada Foundation for Innovation, Canada Research Chair, CIHR, Centre for Aging and Brain Health Innovation, NIH, Ontario Ministry of Health and Long-Term Care, Ontario Ministry of Research and Innovation, and the Weston Brain Institute; an investigator-initiated study in-kind equipment support from Newronika; in-kind research online accounts from Scientific Brain Training Pro; participated in 2021 in 1 advisory board meeting for Biogen Canada; and is an inventor on the US Provisional Patent No. 17/396,030 that describes cell-based assays and kits for assessing serum cholinergic receptor activity. Dr Vila-Rodriguez reports personal fees from Allergan; nonfinancial support from MagVenture outside the submitted work; research support from CIHR, Brain Canada, Michael Smith Foundation for Health Research, Vancouver Coastal Health Research Institute, and Weston Brain Institute for investigator-initiated research; philanthropic support from Seedlings Foundation; in-kind equipment support for an investigator-initiated trial from MagVenture; and has received honoraria for participation in advisory board for Janssen. Dr Daskalakis reports research and equipment in-kind support from Brainsway and Magventure; served on the scientific advisory board of Brainsway and Gazebo Health outside the submitted work; support from the National Institutes of Mental Health, the CIHR, Brain Canada, and the Temerty Family and Grant Family Foundations. Dr Downar reports grants from CIHR, NIH, Foundation for OCD Research, Arrell Family Foundation, and Toronto General and Western Hospital Foundation; personal fees from Salience Health Solutions, Neurostim TMS, and Mindful Health Solutions (consulting); nonfinancial support from MagVenture (in-kind equipment support) outside the submitted work; research support from National Institute of Mental Health, Brain Canada, the Canadian Biomarker Integration Network in Depression, the Ontario Brain Institute, the Klarman Family Foundation, the Arrell Family Foundation, the Edgestone Foundation; travel stipend from Lundbeck and from ANT Neuro; and has served as an advisor to BrainCheck. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> The study was supported by the <funding-source rid="sp1">Temerty Family Foundation</funding-source> and <funding-source rid="sp2">Campbell Family Mental Health Research Institute</funding-source> at the<funding-source rid="sp3"> Centre for Addiction and Mental Health</funding-source> and was funded by <funding-source rid="sp4">Canadian Institutes of Health Research</funding-source> (grant PJT-148840).</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-YOI220060-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Additional Contributions:</bold> We thank the paid clinical research staff at Centre for Addiction and Mental Health (Elizabeth Hollingdrake, MA, MSc, and Dov Millstone, MPH) and the participants of the FOUR-D study.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2022-09-21T10:00">
                <day>21</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <month>11</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>21</day>
                <month>9</month>
                <year>2022</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>79</volume>
              <issue>11</issue>
              <fpage>1065</fpage>
              <lpage>1073</lpage>
              <history>
                <date date-type="received">
                  <day>5</day>
                  <month>5</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>29</day>
                  <month>7</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2022 Blumberger DM et al. <italic>JAMA Psychiatry</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamapsychiatry-e222862.pdf">jamapsychiatry-e222862.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/archpsyc/fullarticle/10.1001/jamapsychiatry.2022.2862"/>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This randomized noninferiority trial establishes the effectiveness and tolerability of theta burst stimulation compared with standard repetitive transcranial magnetic stimulation in older adults with treatment-resistant depression.</p>
              </abstract>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-yoi220060-1">
                  <title>Question</title>
                  <p>Is bilateral theta burst stimulation noninferior to standard bilateral repetitive transcranial magnetic stimulation (rTMS) in older adults with treatment-resistant depression?</p>
                </sec>
                <sec id="ab-yoi220060-2">
                  <title>Findings</title>
                  <p>In this randomized noninferiority trial of 172 participants, improvement on the primary clinical measure (Montgomery-Åsberg Depression Rating Scale) and all secondary clinical outcome measures in patients receiving bilateral theta burst stimulation were robustly noninferior to those receiving standard bilateral rTMS. Additionally, cognitive outcomes and dropout rates were similar between groups.</p>
                </sec>
                <sec id="ab-yoi220060-3">
                  <title>Meaning</title>
                  <p>In older adults with treatment-resistant depression, bilateral theta burst stimulation compared with standard bilateral rTMS achieved noninferior reduction in depression symptoms.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-yoi220060-4">
                  <title>Importance</title>
                  <p>Treatment-resistant depression (TRD) is common in older adults. Bilateral repetitive transcranial magnetic stimulation (rTMS) of the dorsolateral prefrontal cortex for 48 minutes has demonstrated efficacy in TRD. Theta burst stimulation (TBS), a newer form of rTMS, can also be delivered bilaterally using left intermittent TBS and right continuous TBS for only 4 minutes.</p>
                </sec>
                <sec id="ab-yoi220060-5">
                  <title>Objective</title>
                  <p>To establish the effectiveness and tolerability of TBS compared with standard rTMS in older adults with TRD.</p>
                </sec>
                <sec id="ab-yoi220060-6">
                  <title>Design, Setting, and Participants</title>
                  <p>In this randomized noninferiority trial with open treatment and blinded assessors, recruitment occurred between December 2016 and March 2020. The trial was conducted at the Centre for Addiction and Mental Health in Toronto, Ontario, Canada and included outpatients 60 years and older with a diagnosis of depression, moderate severity, and nonresponse to 1 or more antidepressant trial of adequate dosage and duration or intolerance of 2 or more trials.</p>
                </sec>
                <sec id="ab-yoi220060-7">
                  <title>Interventions</title>
                  <p>Participants were randomized to receive a course of 4 to 6 weeks of either bilateral standard rTMS or TBS.</p>
                </sec>
                <sec id="ab-yoi220060-8">
                  <title>Main Outcomes and Measures</title>
                  <p>The primary outcome measure was change in Montgomery-Åsberg Depression Rating Scale; secondary outcome measures included the 17-item Hamilton Rating Scale for Depression, Quick Inventory of Depressive Symptomatology (16-item) (self-report), and dropout rates. A noninferiority margin of 2.75 points was used for the primary outcome. All participants who attained the primary completion point of 4 weeks were analyzed.</p>
                </sec>
                <sec id="ab-yoi220060-9">
                  <title>Results</title>
                  <p>A total of 87 participants (mean [SD] age, 67.1 [6.7] years; 47 [54.0%] female) were randomized to standard bilateral rTMS and 85 (mean [SD] age, 66.3 [5.3] years; 45 [52.9%] female) to TBS, of whom 85 (98%) and 79 (93%) were assessed for the primary outcome, respectively, whereas tolerability was assessed in all randomized participants. In the rTMS group, 4 (4.6%) were American Indian, reported other, or preferred not to answer; 5 (5.8%) were Asian; and 78 (89.7%) were White. In the TBS group, 6 (7.1%) were Asian, 2 (2.4%) were Black or reported other, and 77 (90.3%) were White. Mean (SD) Montgomery-Åsberg Depression Rating Scale total scores improved from 25.6 (4.0) to 17.3 (8.9) for rTMS and 25.7 (4.7) to 15.8 (9.1) for TBS (adjusted difference, 1.55; lower 95% CI −0.67), establishing noninferiority for TBS. The all-cause dropout rates were relatively similar between groups (rTMS: 2 of 87 [2.3%]; TBS: 6 of 85 [7.1%]; <italic>P</italic> = .14; χ<sup>2</sup> = 2.2).</p>
                </sec>
                <sec id="ab-yoi220060-10">
                  <title>Conclusions and Relevance</title>
                  <p>In older adults with TRD, bilateral TBS compared with standard bilateral rTMS achieved noninferior reduction in depression symptoms. Both treatments had low and similar dropout rates. Using TBS rather than rTMS could increase access to treatment several-fold for older adults with TRD.</p>
                </sec>
                <sec id="ab-yoi220060-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02998580" ext-link-type="uri">NCT02998580</ext-link></p>
                </sec>
              </abstract>
              <funding-group>
                <award-group>
                  <funding-source id="sp1">Temerty Family Foundation</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp2">Campbell Family Mental Health Research Institute</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp3"> Centre for Addiction and Mental Health</funding-source>
                </award-group>
              </funding-group>
              <funding-group>
                <award-group>
                  <funding-source id="sp4">Canadian Institutes of Health Research</funding-source>
                </award-group>
              </funding-group>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-YOI220060">
              <title>Introduction</title>
              <p>Depression is the most common and treatable mental disorder in later life, making it a major public health concern,<sup><xref rid="yoi220060r1" ref-type="bibr">1</xref></sup> and 7% of older adults develop major depressive disorder.<sup><xref rid="yoi220060r2" ref-type="bibr">2</xref></sup> Late-life depression is further complicated by comorbid physical illness and is associated with high rates of disability, mortality, and health care utilization.<sup><xref rid="yoi220060r1" ref-type="bibr">1</xref></sup> Importantly, depression is an important treatment target for dementia prevention as it is a modifiable risk factor.<sup><xref rid="yoi220060r3" ref-type="bibr">3</xref></sup></p>
              <p>Current pharmacological treatments for late-life depression have well-established but modest efficacy, with rates of nonresponse to first-line antidepressants ranging from 55% to 81%.<sup><xref rid="yoi220060r1" ref-type="bibr">1</xref></sup> Nonresponse to first-line antidepressant treatment in older adult patients contributes to diminished quality of life.<sup><xref rid="yoi220060r1" ref-type="bibr">1</xref></sup> As a result, treatment-resistant depression (TRD) in older adults has been identified as a priority area for research.<sup><xref rid="yoi220060r4" ref-type="bibr">4</xref></sup></p>
              <p>Repetitive transcranial magnetic stimulation (rTMS) is a treatment that involves direct stimulation of cortical neurons using focused magnetic field pulses; rTMS of the left side of the dorsolateral prefrontal cortex (DLPFC) at 10 Hz is a well-tolerated, evidence-based treatment for TRD.<sup><xref rid="yoi220060r5" ref-type="bibr">5</xref></sup> However, in older adults, most rTMS studies to date have been limited by suboptimal stimulation parameters, small sample sizes, and insufficient treatment durations.<sup><xref rid="yoi220060r6" ref-type="bibr">6</xref></sup> While optimal parameters for rTMS are still in the process of being established, our group found in 2 separate studies superior remission rates with bilateral stimulation (40%) compared with both left-unilateral (0%) and sham (0%) stimulation in older patients with TRD.<sup><xref rid="yoi220060r7" ref-type="bibr">7</xref></sup></p>
              <p>Potential therapeutic advantages of bilateral stimulation can be offset by the need for longer treatment sessions to stimulate both hemispheres sequentially (ie, 30 to 60 minutes). Long sessions reduce treatment capacity; thus, for protocols that involve stimulation of more than 1 target per session, it is particularly desirable to develop techniques for reducing the overall session length. Theta burst stimulation (TBS), which uses patterned bursts of stimulation applied over a fraction of the time than standard treatments,<sup><xref rid="yoi220060r8" ref-type="bibr">8</xref></sup> may be of value in treating older adults with TRD in this regard. TBS may be a more potent physiologic form of stimulation than standard rTMS as it is based on coupling of γ and θ frequency rhythms of the brain.<sup><xref rid="yoi220060r9" ref-type="bibr">9</xref></sup> Preclinical research suggests that TBS can achieve similar or more potent effects on neural plasticity, with durable effects ensuing from 600 pulses of intermittent TBS (iTBS) over 3 minutes or 600 pulses of continuous TBS (cTBS) over 40 seconds.<sup><xref rid="yoi220060r10" ref-type="bibr">10</xref></sup> Previous work has demonstrated that a 3-minute session of 600 pulses of iTBS achieves a similar reduction in depressive symptoms<sup><xref rid="yoi220060r9" ref-type="bibr">9</xref></sup> compared with the standard US Food and Drug Administration (FDA)–cleared 10-Hz rTMS protocol.<sup><xref rid="yoi220060r11" ref-type="bibr">11</xref></sup> Bilateral TBS protocols have also been studied in major depressive disorder, and they yield higher remission rates than sham TBS<sup><xref rid="yoi220060r12" ref-type="bibr">12</xref></sup> while still reducing session duration.</p>
              <p>As such, we conducted a randomized noninferiority trial to investigate the relative effectiveness of standard sequential bilateral rTMS (47.5 minutes) vs bilateral TBS (4 minutes) in older adults with TRD. A noninferiority rather than equivalence design was chosen because of the asymmetric time advantage of TBS. We hypothesized that bilateral TBS would be noninferior in reducing depressive symptoms compared with standard bilateral rTMS. Additionally, we compared the effects of TBS vs standard rTMS on cognition, self-reported adverse effects (including pain), and all-cause dropout rates.</p>
            </sec>
            <sec id="H1-2-YOI220060">
              <title>Methods</title>
              <sec id="H2-1-YOI220060">
                <title>Setting and Participants</title>
                <p>The trial was conducted at an academic health center (Centre for Addiction and Mental Health, Toronto, Ontario, Canada) after research ethics board approval. The trial protocol is available in <xref rid="note-YOI220060-1-s" ref-type="supplementary-material">Supplement 1</xref>. All participants provided written, informed consent to participate. From December 2016 to March 2020, we recruited outpatient adults 60 years and older with major depressive disorder confirmed by the Mini-International Neuropsychiatric Interview,<sup><xref rid="yoi220060r13" ref-type="bibr">13</xref></sup> moderate severity episode based on a Montgomery-Åsberg Depression Rating Scale (MADRS)<sup><xref rid="yoi220060r14" ref-type="bibr">14</xref></sup> score of 18 or higher, nonresponse to 1 or more antidepressant trial of adequate dosage and duration using the Antidepressant Treatment History Form<sup><xref rid="yoi220060r15" ref-type="bibr">15</xref></sup> or intolerance of 2 or more antidepressants, no increase or initiation of psychotropic medication 4 weeks prior to screening, and normal prestudy blood work results. Exclusion criteria were substance misuse or dependence within the last 3 months, unstable physical illness, active suicidal intent, current psychotic symptoms, bipolar disorder, other psychiatric disorder causing greater impairment than major depressive disorder, dementia, Short Blessed Test<sup><xref rid="yoi220060r16" ref-type="bibr">16</xref></sup> total score of more than 10, electroconvulsive therapy or rTMS during the current episode, seizure disorder or lesion-related seizure, intracranial implant or metal in the cranium, implanted electronic device, and anticonvulsant use or benzodiazepine more than or equal to lorazepam 2 mg/d equivalents. During the treatment course, preexisting pro re nata medications were allowed; pro re nata benzodiazepine use was discouraged and had to be within the allowable limits. Race and ethnicity were collected by self-report.</p>
              </sec>
              <sec id="H2-2-YOI220060">
                <title>Randomization and Blinding</title>
                <p>Outpatients were randomized by personnel external to the clinical team using a computer-based algorithm and allocated in a 1:1 ratio to the standard bilateral protocol or the bilateral TBS protocol. Randomly permuted blocks, with stratification by level of treatment resistance (0 or 1 vs &gt;1 adequate trial). Nontransparent, sealed envelopes with a randomization identification on the outside and treatment assignment on the inside were used for allocation. The randomization identification was assigned, and treatment allocation was accessed immediately prior to the first session by the treating technician. Both technicians and participants (because of the different duration of sessions) were aware of the treatment condition. Participants were instructed not to discuss their treatment with others in the clinic. Outcome raters were blinded to treatment assignment and located on another floor.</p>
              </sec>
              <sec id="H2-3-YOI220060">
                <title>Standard rTMS and TBS Procedures</title>
                <p>Following baseline magnetic resonance imaging (MRI), participants underwent neuronavigation using the Visor 2 system (Advanced Neuro Therapeutics) to position the transcranial magnetic stimulation (TMS) coil at a minimum distance from a left-sided DLPFC target coordinate defined based on anticorrelation to the subgenual cingulate cortex and its right-hemisphere counterpart (MNI-152 stereotaxic coordinate [x ± 38 y + 44 z + 26]).<sup><xref rid="yoi220060r17" ref-type="bibr">17</xref></sup> Participants who could not tolerate the MRI (because of claustrophobia) were allowed to undergo treatment using an approximated method.<sup><xref rid="yoi220060r18" ref-type="bibr">18</xref></sup></p>
                <p>Treatment was delivered with a MagPro X100 stimulator equipped with the B70 fluid-cooled coil (MagVenture). Standard sequential bilateral rTMS consisted of 1-Hz stimulation (120% resting motor threshold [RMT], 600 pulses over 10 minutes) to the right DLPFC, followed by standard FDA-cleared 10-Hz stimulation (120% RMT, 3000 pulses: 4 seconds on, 26 seconds off over 37.5 minutes) to the left DLPFC. Sequential bilateral TBS was delivered at the same stimulation sites and intensity (120% RMT) with right-sided cTBS (triplet burst pulses at 50 Hz, repeated at 5 Hz for 600 pulses over 40 seconds) followed by FDA-cleared left-sided iTBS (triplet burst pulses at 50 Hz, repeated at 5 Hz, 2 seconds on, 8 seconds off, for 600 pulses over 3 minutes 9 seconds). An adaptive titration to 120% RMT was used within the first 4 treatments to aid with tolerability.</p>
                <p>As done in clinical practice, each participant’s RMT was determined using visual observation.<sup><xref rid="yoi220060r5" ref-type="bibr">5</xref></sup> Participants received 20 initial daily sessions over 4 weeks and were offered an additional 10 daily sessions over 2 additional weeks if they did not achieve remission after 20 sessions. Participants who missed scheduled treatment days due to intercurrent illness or scheduling conflicts received the entire 20 to 30 treatments over a longer time period. Participants missing more than 3 consecutive treatments were withdrawn.</p>
              </sec>
              <sec id="H2-4-YOI220060">
                <title>Clinical Measures</title>
                <p>Clinical outcome measures were assessed at baseline, after every 5 sessions, and then 1, 4, and 12 weeks after treatment. MADRS score was the primary outcome measure from baseline to end of treatment. Secondary depression symptom severity outcome measures included the 17-item Hamilton Rating Scale for Depression (HRSD-17)<sup><xref rid="yoi220060r19" ref-type="bibr">19</xref></sup> and the Quick Inventory of Depressive Symptomatology (16-item) (self-report) (QIDS-SR-16).<sup><xref rid="yoi220060r20" ref-type="bibr">20</xref></sup> Response rates (defined as ≥50% score improvement from baseline) and remission rates (defined as MADRS score ≤10, HRDS-17 score ≤ 7, and QIDS-SR-16 score ≤ 5) were secondary outcome measures. To assess other potential characteristics associated with response to rTMS, we obtained the Brief Symptom Inventory–anxiety<sup><xref rid="yoi220060r21" ref-type="bibr">21</xref></sup> and the Cumulative Illness Rating Scale for Geriatrics<sup><xref rid="yoi220060r22" ref-type="bibr">22</xref></sup> scores.</p>
              </sec>
              <sec id="H2-5-YOI220060">
                <title>Safety and Tolerability Measures</title>
                <p>Because cognition is typically impaired in late-life depression<sup><xref rid="yoi220060r23" ref-type="bibr">23</xref></sup> and an important predictor of antidepressant outcome,<sup><xref rid="yoi220060r24" ref-type="bibr">24</xref></sup> a cognitive battery was administered (baseline, end of treatment, and 12 weeks posttreatment). Executive function was assessed with the Delis-Kaplan Executive Function System Color-Word Interference test<sup><xref rid="yoi220060r25" ref-type="bibr">25</xref></sup> and the National Institutes of Health Toolbox Flanker Inhibitory Control and Attention Test.<sup><xref rid="yoi220060r26" ref-type="bibr">26</xref></sup> Memory was assessed with the California Verbal Learning Test–second edition.<sup><xref rid="yoi220060r27" ref-type="bibr">27</xref></sup> Global cognition was assessed with 3 different versions of the Montreal Cognitive Assessment.<sup><xref rid="yoi220060r28" ref-type="bibr">28</xref></sup></p>
                <p>At each session, self-reported adverse effects were queried, and participants self-rated pain intensity on a verbal analogue scale (0 = no pain, 10 = intolerable pain). We recorded the number of sessions required to reach 120% RMT by session end and number of sessions required to start the session at this target intensity. Serious adverse events (SAEs) and reasons for treatment discontinuation were recorded.</p>
              </sec>
              <sec id="H2-6-YOI220060">
                <title>Statistical Analysis</title>
                <p>According to the National Institute of Clinical Health and Excellence, a clinically meaningful difference between drug and placebo is defined by 3 points or more on a depression rating scale.<sup><xref rid="yoi220060r29" ref-type="bibr">29</xref></sup> For the primary analysis, based on our previous rTMS trial in older adults with TRD,<sup><xref rid="yoi220060r7" ref-type="bibr">7</xref></sup> we used a δ of 2.75 and a standard deviation of change of 7.8 and estimated a sample size of 200 participants was required to determine if bilateral TBS was noninferior to bilateral rTMS with 80% power and a 1-sided alpha of 0.05. As intention-to-treat analyses can bias in favor of noninferiority, the primary analysis included participants who had completed the majority of 4 weeks of treatment.<sup><xref rid="yoi220060r30" ref-type="bibr">30</xref></sup> Two sensitivity analyses were conducted: one excluded 7 participants who were not able to receive an MRI and the other used the intention-to-treat sample.</p>
                <p>To assess the primary outcome analysis, baseline-adjusted change was estimated from an analysis of covariance model using final MADRS score as the outcome and baseline score as the adjustment covariate with a δ = 2.75. The null hypothesis was baseline-adjusted mean final MADRS score for standard bilateral rTMS would be at least 2.75 points better than bilateral TBS, and the alternative (noninferiority) hypothesis that baseline-adjusted mean final MADRS score for bilateral rTMS would be less than 2.75 points better than bilateral TBS. The same noninferiority δ = 2.75 was used for HRDS-17 and QIDS-SR-16 scores. Based on raw mean difference between active and sham rTMS for response (21% difference) and remission (14% difference) from a previous meta-analysis,<sup><xref rid="yoi220060r31" ref-type="bibr">31</xref></sup> a noninferiority δ = 15% was used to compare response rates and a noninferiority δ = 10% was used to compare remission rates. Linear mixed-effect models were used to evaluate differences on the cognitive measures.</p>
                <p>For tolerability comparisons, participants’ mean pain score across all treatment sessions were calculated for each group and compared. The prevalence of reported adverse effects and the proportion of participants reporting adverse effects were compared. Finally, rates of all-cause dropout from all causes were compared using Fisher exact test. The analysis was conducted with R version 4.1.2 (R Foundation) and the lme 4 package v1.1-29.</p>
              </sec>
            </sec>
            <sec id="H1-3-YOI220060">
              <title>Results</title>
              <p><xref rid="yoi220060t1" ref-type="table">Table 1</xref> summarizes the characteristics of the intention-to-treat sample of 172 participants randomized to receive treatment by the early stages of the COVID-19 pandemic in March 2020; new recruitment was halted when it became infeasible due to persistent public health restrictions in the province of Ontario, Canada. A total of 164 participants completed the greater part of 4 weeks of treatment and were included in the primary analysis (<xref rid="yoi220060f1" ref-type="fig">Figure 1</xref>). A total of 87 participants (mean [SD] age, 67.1 [6.7] years; 47 [54.0%] female) were randomized to standard bilateral rTMS and 85 (mean [SD] age, 66.3 [5.3] years; 45 [52.9%] female) to TBS. In the rTMS group, 4 (4.6%) were American Indian, reported other, or preferred not to answer; 5 (5.8%) were Asian; and 78 (89.7%) were White. In the TBS group, 6 (7.1%) were Asian, 2 (2.4%) were Black or reported other, and 77 (90.3%) were White.</p>
              <table-wrap position="float" id="yoi220060t1">
                <label>Table 1. </label>
                <caption>
                  <title>Baseline Demographic and Clinical Characteristics</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="52.09%" span="1"/>
                  <col width="26.07%" span="1"/>
                  <col width="21.84%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                      <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SD)</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">rTMS (n = 87)</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">TBS (n = 85)</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">67.1 (6.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">66.3 (5.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Female, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">47 (54.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">45 (52.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Male, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">40 (46)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">40 (47.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Years of education</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.38 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.16 (3.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">MADRS score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">25.7 (4.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">26 (4.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">HRSD-17 score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">18.3 (4.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">18.7 (4.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">QIDS score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15.6 (4.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">16.1 (4.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BSI-A score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">11.0 (5.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.0 (5.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age at onset, y</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30.2 (19.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">31.6 (18.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Episode duration, mo</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">50.2 (82.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">71.5 (109.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of ECT, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14 (16.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8 (9.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">History of rTMS, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15 (17.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">12 (14.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Psychotherapy during the episode, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30 (34.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">28 (32.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Pharmacotherapy during treatment, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No antidepressant medication</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">11 (12.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">13 (15.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hypnotic Z drugs</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">20 (23.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14 (16.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Benzodiazepine use</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">34 (39.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">42 (49.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antidepressant alone</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">36 (41.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">30 (35.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antidepressant combination</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">20 (23.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">13 (15.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antipsychotic augmentation</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">21 (32.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">19 (22.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lithium augmentation</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (7.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Antipsychotic alone</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1 (1.1)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2 (2.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Stimulant</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">7 (8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">7 (8.2)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Cognitive measures</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline flanker task score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">89.1 (10.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">89.5 (9.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Baseline DKEFS score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Color naming task scaled score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8.6 (3.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.5 (3.0)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Color word task scaled score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.3 (3.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.6 (2.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Inhibition scaled score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.1 (2.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.4 (2.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Inhibition/switching scaled score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">10.7 (2.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">11.1 (2.5)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1"> Baseline CVLT-II score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> List A Trials 1-5 T-Score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">47.3 (10.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">47.8 (10.9)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> List A Short-Delay Free Recall Z score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.17 (1.12)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.13 (1.17)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> List A Long-Delay Free Recall Z score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.28 (1.11)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">−0.25 (1.19)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Baseline MOCA score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">24.8 (3.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">25.1 (3.3)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Previous treatment history, No. (%)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                      <td valign="top" align="left" rowspan="1" colspan="1"/>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unable to tolerate 2 trials</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (6.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6 (7.1)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 1 Failed trial</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">26 (29.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">25 (29.4)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 2 Failed trials</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">23 (26.4)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">27 (31.8)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 3 Failed trials</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17 (19.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15 (17.6)</td>
                    </tr>
                    <tr>
                      <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> ≥4 Failed trials</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">15 (17.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">12 (14.1)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: BSI-A, Brief Symptom Inventory–Anxiety; CVLT-II, California Verbal Learning Test (Second Edition); DKEFS, Delis-Kaplan Executive Function System; ECT, electroconvulsive therapy; HRSD-17, 17-item Hamilton Depression Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MOCA, Montreal Cognitive Assessment; QIDS, Quick Inventory of Depressive Symptomatology; rTMS, repetitive transcranial magnetic stimulation; TBS, theta burst stimulation.</p>
                </table-wrap-foot>
              </table-wrap>
              <fig position="float" id="yoi220060f1" fig-type="figure">
                <label>Figure 1. </label>
                <caption>
                  <title>CONSORT Flow Diagram</title>
                  <p>PI indicates principal investigator; rTMS, repetitive transcranial magnetic stimulation; TBS, theta burst stimulation.</p>
                </caption>
                <graphic xlink:href="jamapsychiatry-e222862-g001" position="float"/>
              </fig>
              <sec id="H2-7-YOI220060">
                <title>Efficacy Outcomes</title>
                <sec id="H3-1-YOI220060">
                  <title>Primary Analysis</title>
                  <p>Final MADRS score change showed an estimated adjusted difference of 1.55 points favoring TBS, with a lower 95% CI of −0.67, lower than the a priori noninferiority <italic>δ = </italic>2.75 points. Additional analyses demonstrated noninferiority at all follow-up time points (eTable 1 in <xref rid="note-YOI220060-1-s" ref-type="supplementary-material">Supplement 2</xref>) and in the sensitivity analysis sample (n = 157) (estimated adjusted difference of 1.22 points favoring TBS, with a lower 95% CI of −1.06 points). A comparison of the change in MADRS scores over time for the 2 groups is depicted in <xref rid="yoi220060f2" ref-type="fig">Figure 2</xref>A and the relative difference in change compared to the noninferiority margin in <xref rid="yoi220060f2" ref-type="fig">Figure 2</xref>B.</p>
                  <fig position="float" id="yoi220060f2" fig-type="figure">
                    <label>Figure 2. </label>
                    <caption>
                      <title>Relative Change and Differences in Depression Scores</title>
                      <p>A, Change in Montgomery-Åsberg Depression Rating Scale (MADRS) scores over time in the standard bilateral repetitive transcranial magnetic stimulation (n = 85) and bilateral theta burst stimulation (TBS) (n = 79) groups. Points represent mean scores and bars represent 90% CI. B, Estimated adjusted difference shown with 2-sided lower and upper 90% CIs, though the test of noninferiority was conducted using a 1-side lower 95% CI. The dotted line represents the noninferiority <italic>δ</italic> = −2.75 points. See Table 2 for estimated adjusted differences and tests of noninferiority. HRSD indicates 17-item Hamilton Rating Scale for Depression; QIDS-SR-16, Quick Inventory of Depressive Symptomatology (16-item) (self-report).</p>
                    </caption>
                    <graphic xlink:href="jamapsychiatry-e222862-g002" position="float"/>
                  </fig>
                </sec>
                <sec id="H3-2-YOI220060">
                  <title>Secondary Outcome Analyses</title>
                  <p>On all secondary outcome measures, TBS also demonstrated noninferiority to standard bilateral rTMS (<xref rid="yoi220060t2" ref-type="table">Table 2</xref>) and at all follow-up time points (eTable 1 in <xref rid="note-YOI220060-1-s" ref-type="supplementary-material">Supplement 2</xref>). The MADRS response rate for TBS was 44.3% (35 of 79) compared with 32.9% (28 of 85) for standard bilateral rTMS with an estimated adjusted difference of 11.4% favoring TBS, with a lower 95% CI of −1.1%, smaller than the noninferiority <italic>δ &lt; </italic>15%. Similarly, the MADRS remission rate for TBS was 35.4% (28 of 79) compared with 32.9% (28 of 85) for standard bilateral rTMS with an estimated adjusted difference of 2.5% favoring TBS, with a lower 95% CI of −9.7%, smaller than the noninferiority <italic>δ &lt; </italic>10%.</p>
                  <table-wrap position="float" id="yoi220060t2">
                    <label>Table 2. </label>
                    <caption>
                      <title>Response, Remission, and Change in Depression Severity Scores<xref rid="yoi220060t2n1" ref-type="table-fn"><sup>a</sup></xref></title>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col width="29.16%" span="1"/>
                      <col width="14.6%" span="1"/>
                      <col width="13.55%" span="1"/>
                      <col width="26.21%" span="1"/>
                      <col width="16.48%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Outcome measure</th>
                          <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Mean (SD)</th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Estimated adjusted difference, % (90% CI)<xref rid="yoi220060t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1"><italic>P</italic> value<xref rid="yoi220060t2n2" ref-type="table-fn"><sup>b</sup></xref></th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">rTMS (n = 85)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">TBS (n = 79)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                            <bold>MADRS</bold>
                          </td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline score</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25.6 (4.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25.7 (4.7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Final</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">17.3 (8.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">15.8 (9.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.547 (−0.66 to 3.75)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Response rate, No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">28 (32.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">35 (44.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">11.40 (−1.10 to 23.80)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Remission rate, No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">28 (32.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">28 (35.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2.50 (−9.70 to 14.70)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.046</td>
                        </tr>
                        <tr>
                          <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                            <bold>HRSD-17</bold>
                          </td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18.4 (4.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18.5 (4.7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Final</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">12.3 (6.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">11.4 (6.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0.917 (−0.72 to 2.56)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Response rate, No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">24 (29.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">31 (41.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">12.30 (−0.30 to 24.90)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Remission rate, No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">22 (27.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25 (33.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.60 (−5.50 to 18.80)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.01</td>
                        </tr>
                        <tr>
                          <td colspan="5" valign="top" align="left" scope="col" rowspan="1">
                            <bold>QIDS-16</bold>
                          </td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Baseline</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">15.7 (4.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">15.9 (4.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Final</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10.8 (6.0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">9.7 (6.1)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1.268 (−0.1 to 2.67)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Response rate, No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">30 (35.7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">35 (44.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">8.60 (−4.00 to 21.20)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.001</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Remission rate, No. (%)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18 (21.4)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">25 (31.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">10.20 (−1.10 to 21.50)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">.002</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BSI-A baseline</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">11.1 (5.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">9.8 (5.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">BSI-A final</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6.6 (5.8)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">5.7 (5.2)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0.341 (−0.99 to 1.67)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Abbreviations: BSI-A, Brief Symptom Inventory–anxiety; HRSD-17, 17-item Hamilton Rating Scale for Depression; MADRS, Montgomery-Åsberg Depression Rating Scale; NA, not applicable; QIDS-16, 16-item Quick Inventory of Depressive Symptomatology; rTMS, repetitive transcranial magnetic stimulation; TBS, theta burst stimulation.</p>
                      <fn id="yoi220060t2n1">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p>For estimated adjusted difference values, positive values indicate greater change in the bilateral TBS group, while negative values indicate greater change in the standard bilateral rTMS group.</p>
                      </fn>
                      <fn id="yoi220060t2n2">
                        <label>
                          <sup>b</sup>
                        </label>
                        <p>Corresponds to the lower 95% CI of the 1-sided test for noninferiority. <italic>P</italic> values indicate the significance of rejecting the null hypothesis based on the change in symptoms in the 2 groups and on a noninferiority δ of 15% for the proportion of responders and 10% for the proportion of remitters.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="H3-3-YOI220060">
                  <title>Cognitive Safety</title>
                  <p>There were no substantial changes on any of the cognitive measures and no significant differences between standard rTMS and TBS on any of the cognitive measures (eTable 3 in <xref rid="note-YOI220060-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
                </sec>
                <sec id="H3-4-YOI220060">
                  <title>Tolerability Outcomes</title>
                  <p>The number of reported adverse events for headache, nausea, dizziness, or other adverse events were relatively similar between standard rTMS and TBS (<xref rid="yoi220060t3" ref-type="table">Table 3</xref>). Pain scores were significantly lower in the rTMS than in the TBS group (mean [SD]: right side, 1.66 [1.79] for standard rTMS and 3.59 [2.45] for TBS; left side, 2.80 [1.99] for standard rTMS and 4.01 [2.55] for TBS). The number of days to reach target intensity on the right side was also higher in the TBS group (mean [SD]: TBS, 4.6 [4.1] days vs standard rTMS, 2.9 [3.5] days).</p>
                  <table-wrap position="float" id="yoi220060t3">
                    <label>Table 3. </label>
                    <caption>
                      <title>Tolerability</title>
                    </caption>
                    <table frame="hsides" rules="groups">
                      <col width="39.58%" span="1"/>
                      <col width="40.61%" span="1"/>
                      <col width="19.81%" span="1"/>
                      <thead>
                        <tr>
                          <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Variable</th>
                          <th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants who experienced each adverse reaction, No. (%)<xref rid="yoi220060t3n1" ref-type="table-fn"><sup>a</sup></xref></th>
                        </tr>
                        <tr>
                          <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">rTMS (n = 87)</th>
                          <th valign="top" align="left" scope="col" rowspan="1" colspan="1">TBS (n = 85)</th>
                        </tr>
                      </thead>
                      <tbody>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Headache</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">49 (56.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">46 (54.1)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nausea</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (6.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (8.2)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Dizziness</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">17 (19.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">18 (21.2)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unrelated medical problem</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">37 (42.5)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">34 (40)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Fatigue</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">5 (5.7)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">5 (5.9)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Insomnia</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (2.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">1 (1.2)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Anxiety/agitation</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">7 (8.0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">8 (9.4)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Back/neck pain</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">6 (6.9)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">9 (10.6)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Unrelated accidents</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Vomiting</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tinnitus</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (2.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">0 (0)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Migraine aura</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">4 (4.6)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">3 (3.5)</td>
                        </tr>
                        <tr>
                          <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Abnormal sensations</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (2.3)</td>
                          <td valign="top" align="left" rowspan="1" colspan="1">2 (2.4)</td>
                        </tr>
                      </tbody>
                    </table>
                    <table-wrap-foot>
                      <p>Abbreviations: rTMS, repetitive transcranial magnetic stimulation; TBS, theta burst stimulation.</p>
                      <fn id="yoi220060t3n1">
                        <label>
                          <sup>a</sup>
                        </label>
                        <p><italic>P</italic> &gt; .05 on Fisher exact tests for each pair of proportions. Participants were queried at each treatment about adverse reactions.</p>
                      </fn>
                    </table-wrap-foot>
                  </table-wrap>
                </sec>
                <sec id="H3-5-YOI220060">
                  <title>Early Discontinuation and SAEs</title>
                  <p>Two of 87 participants undergoing rTMS (2.3%) and 6 of 85 participants undergoing TBS (7.1%) discontinued treatment prior to the primary end point (<xref rid="yoi220060f1" ref-type="fig">Figure 1</xref>). During the intervention period, SAEs occurred in 0 of 87 participants undergoing rTMS and 1 of 85 participant undergoing TBS (1.2%) (psychiatric admission for depression); during the postintervention follow-up, SAEs occurred in 2 of 87 participants undergoing rTMS (2.3%) (2 hospitalizations for surgery) and 1 of 85 participant undergoing TBS (1.2%) (psychiatric admission for depression).</p>
                </sec>
              </sec>
            </sec>
            <sec id="H1-4-YOI220060">
              <title>Discussion</title>
              <p>To our knowledge, we report on the largest randomized clinical trial of nonconvulsive neuromodulation in older adults with TRD. For these patients, our findings provide strong evidence that TBS is noninferior to standard rTMS in reducing depressive symptoms. Noninferiority was demonstrated on all clinician-rated and self-report psychiatric symptom measures at all assessment points, including 12 weeks after treatment. Both rTMS and TBS demonstrated cognitive safety, with improvement consistent with possible practice effects. There were no differences in self-reported adverse effects or in SAEs. Pain ratings were significantly higher with TBS, particularly with right-sided cTBS where stimulation was delivered in a 40-second continuous train. However, this did not lead to a higher dropout rate. Taken together, these findings suggest that 4-minute sequential bilateral TBS is comparable with standard 47.5-minute bilateral rTMS in older adults with TRD. Importantly, both bilateral treatment protocols incorporated an FDA-cleared left-sided treatment (10-Hz rTMS or iTBS) preceded by right-sided priming (with 1-Hz rTMS or cTBS).</p>
              <p>The remission rate of 35.4% for the bilateral TBS group is clinically important in this sample of older adults with TRD and a mean of 2 antidepressant trials (some with more than 4 trials) and some with substantial cognitive impairment. This remission rate is comparable with those seen in our previous bilateral rTMS trial (33%)<sup><xref rid="yoi220060r7" ref-type="bibr">7</xref></sup> and deep rTMS trial (40%)<sup><xref rid="yoi220060r32" ref-type="bibr">32</xref></sup> and comparable with the remission rate seen with aripiprazole augmentation in older adults with TRD.<sup><xref rid="yoi220060r33" ref-type="bibr">33</xref></sup> In addition, this remission rate is consistent with the remission rate of iTBS (32%) in the THREE-D trial in younger adults with TRD.<sup><xref rid="yoi220060r9" ref-type="bibr">9</xref></sup> Standard bilateral rTMS has been shown to be efficacious in multiple clinical trials and was one of the most effective rTMS protocols in 2 recent network meta-analyses.<sup><xref rid="yoi220060r34" ref-type="bibr">34</xref>,<xref rid="yoi220060r35" ref-type="bibr">35</xref></sup> Both the degree of improvement and the remission rate in our bilateral standard rTMS arm are consistent with results of previous randomized clinical trials and provides assay sensitivity. The present study used bilateral stimulation, rather than the unilateral stimulation in the THREE-D trial, based on data suggesting better response to bilateral stimulation compared with sham in older adults<sup><xref rid="yoi220060r7" ref-type="bibr">7</xref></sup> and data demonstrating efficacy of bilateral cTBS/iTBS compared with sham in adults.<sup><xref rid="yoi220060r12" ref-type="bibr">12</xref>,<xref rid="yoi220060r36" ref-type="bibr">36</xref></sup> However, recent clinical registry data indicate no added benefit for bilateral over unilateral stimulation in a lifespan sample.<sup><xref rid="yoi220060r37" ref-type="bibr">37</xref></sup> Thus, although the addition of 40 seconds of right-sided cTBS to 3 minutes of left-sided iTBS is a minimal increase in treatment time, it may also prove to yield minimal increase in clinical benefit over left-sided iTBS in the community setting. Bio-creep has been raised as a concern in serial noninferiority trials<sup><xref rid="yoi220060r38" ref-type="bibr">38</xref></sup>; the fact that the TBS arm performed better than the standard measure on all measures and outcomes argues against this phenomenon occurring here. Indeed, the TBS arm demonstrated an ongoing improvement up to 4 weeks posttreatment that was superior to standard rTMS. This finding of sustained and progressive improvement is consistent with the possibility that TBS induces greater brain plasticity than standard rTMS protocols.<sup><xref rid="yoi220060r10" ref-type="bibr">10</xref></sup></p>
              <p>Both treatments were well tolerated and had high retention during active treatment (95% retention). As in the THREE-D trial, TBS was associated with higher pain ratings, more pronounced for cTBS. However, this did not translate into a higher dropout rate possibly because of the much shorter duration of stimulation with TBS. Importantly, both treatments showed cognitive safety, with almost all measures demonstrating relatively improved performance after treatment that was sustained in those assessed 12 weeks after treatment.</p>
              <p>The strong noninferiority findings replicate the THREE-D findings in a vulnerable patient population with currently limited antidepressant treatment options. Previous work has suggested that older adults require higher stimulation intensities<sup><xref rid="yoi220060r39" ref-type="bibr">39</xref></sup> to ensure sufficient cortical stimulation. Therefore, we ensured that both groups received stimulation at 120% RMT. While this intensity is consistent with current recommendations for standard rTMS,<sup><xref rid="yoi220060r5" ref-type="bibr">5</xref></sup> there is no current consensus on the optimal intensity for TBS and other studies have used lower intensities.<sup><xref rid="yoi220060r12" ref-type="bibr">12</xref></sup> A recent trial suggested similar outcomes for TBS at 80% vs 120% RMT.<sup><xref rid="yoi220060r40" ref-type="bibr">40</xref></sup> However, the study enrolled mixed-age adults rather than only older adults, as we did. Thus, it remains unclear whether TBS at lower intensities is suitable in older adults who may have a greater degree of prefrontal atrophy.</p>
              <sec id="H2-8-YOI220060">
                <title>Limitations</title>
                <p>Several limitations should be considered. The study was designed to measure the effectiveness of standard sequential bilateral rTMS and bilateral TBS in a real-world sample of older adults with TRD. As such, there was no sham group and participants were aware of their treatment allocation. The decision to compare TBS with standard bilateral TMS rather than sham was a recognition of network meta-analytic findings supporting bilateral standard TMS over sham treatment<sup><xref rid="yoi220060r34" ref-type="bibr">34</xref>,<xref rid="yoi220060r35" ref-type="bibr">35</xref></sup> as well as the widespread use of bilateral standard TMS in the community setting.<sup><xref rid="yoi220060r37" ref-type="bibr">37</xref></sup> However, a sham arm would have allowed for an assessment of the contribution of nonspecific factors. The longer duration of standard treatment involved substantially longer therapeutic contact with technicians, which could have added nonspecific bias in favor of standard rTMS. Despite this relative disadvantage experienced by those in the TBS group, the overall outcomes demonstrated noninferiority and strengthen the overall findings. The possibility that therapeutically important but nonspecific aspects of TMS treatment (ie, routine establishment, behavioral activation, social interaction) might accrue even with brief appointments is encouraging and bears future enquiry. While the trial is one of the largest neurostimulation trials in older adults with TRD, it was nevertheless conducted at a single site. As a result of the COVID-19 pandemic, trial recruitment was halted for several months. When restarting clinical trials was permitted, prolonged and stringent public health measures in Ontario made resuming the trial infeasible. Furthermore, marked changes in the psychosocial and health care environment associated with the pandemic would have introduced confounding factors between pre– and post–COVID-19 cohorts. Despite the truncated recruitment period and the smaller sample than planned, the findings strongly support the noninferiority of TBS and it is highly unlikely that these findings would change with an additional 20 or 30 participants. Similarly, while we prespecified a 1-sided 95% CI for the analysis and more stringent recommendations suggest a 1-sided 97.5% CI, noninferiority findings remained on all measures with this more stringent criterion (eTable 2 in <xref rid="note-YOI220060-1-s" ref-type="supplementary-material">Supplement 2</xref>). The use of MRI neuronavigation is a potential limitation to generalizability, although findings did not change with participants who received approximated treatment with the approximated scalp-based method.<sup><xref rid="yoi220060r18" ref-type="bibr">18</xref></sup> Given that the clinical effectiveness seen in the present study lies in a range similar to that reported in large community-based samples,<sup><xref rid="yoi220060r41" ref-type="bibr">41</xref></sup> future studies may wish to reconsider whether MRI-guided neuronavigation adds additional value over scalp-based heuristics<sup><xref rid="yoi220060r18" ref-type="bibr">18</xref></sup> when the stimulation target is defined from population-based coordinates rather than individualized functional neuroimaging data.<sup><xref rid="yoi220060r42" ref-type="bibr">42</xref></sup> While the left-sided DLPFC target was based on previous work,<sup><xref rid="yoi220060r17" ref-type="bibr">17</xref></sup> there is an absence of any validated stereotaxic target for right-sided DLPFC-rTMS; as such, we mirrored the left stereotaxic coordinate to the right hemisphere following common clinical practice. Finally, the findings at the follow-up time points must be interpreted with caution since some participants were lost to follow-up.</p>
              </sec>
            </sec>
            <sec id="H1-5-YOI220060">
              <title>Conclusions</title>
              <p>In summary, we showed that bilateral TBS was noninferior to standard bilateral rTMS in improving depression, and similarly well tolerated, in a real-world sample of older adults with TRD. Since bilateral TBS takes 4 minutes to deliver, the use of TBS instead of standard rTMS (which takes 47.5 minutes to deliver) could increase the capacity of brain simulation programs that serve older adults. Furthermore, the short-session duration lends itself to potentially accelerated response with multiple treatments per day<sup><xref rid="yoi220060r42" ref-type="bibr">42</xref></sup> and the findings herein suggest that this may be possible using bilateral TBS with older adults with depression. Although there is a pervasive assumption that rTMS in general is not well suited for older adults with TRD, the results of both the THREE-D study<sup><xref rid="yoi220060r43" ref-type="bibr">43</xref></sup> and the present FOUR-D study indicate that rTMS outcomes in older adults can be at least as good, and perhaps better, as in younger adults. Given both its effectiveness and excellent tolerability, bilateral rTMS or TBS could be considered at an earlier stage in the treatment algorithm for older adults with TRD.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-YOI220060">
              <title>References</title>
              <ref id="yoi220060r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></string-name>, <string-name><surname>Lenze</surname><given-names>E</given-names></string-name>, <string-name><surname>Mulsant</surname><given-names>BH</given-names></string-name></person-group>. <article-title>Assessment and treatment of major depression in older adults</article-title>. <source>Handb Clin Neurol</source>. <year>2019</year>;<volume>167</volume>:<fpage>429</fpage>-<lpage>435</lpage>. doi:<pub-id pub-id-type="doi">10.1016/B978-0-12-804766-8.00023-6</pub-id><?supplied-pmid 31753147?><pub-id pub-id-type="pmid">31753147</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kessler</surname><given-names>RC</given-names></string-name>, <string-name><surname>Birnbaum</surname><given-names>H</given-names></string-name>, <string-name><surname>Bromet</surname><given-names>E</given-names></string-name>, <string-name><surname>Hwang</surname><given-names>I</given-names></string-name>, <string-name><surname>Sampson</surname><given-names>N</given-names></string-name>, <string-name><surname>Shahly</surname><given-names>V</given-names></string-name></person-group>. <article-title>Age differences in major depression: results from the National Comorbidity Survey Replication (NCS-R)</article-title>. <source>Psychol Med</source>. <year>2010</year>;<volume>40</volume>(<issue>2</issue>):<fpage>225</fpage>-<lpage>237</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0033291709990213</pub-id><?supplied-pmid 19531277?><pub-id pub-id-type="pmid">19531277</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Livingston</surname><given-names>G</given-names></string-name>, <string-name><surname>Huntley</surname><given-names>J</given-names></string-name>, <string-name><surname>Sommerlad</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Dementia prevention, intervention, and care: 2020 report of the Lancet Commission</article-title>. <source>Lancet</source>. <year>2020</year>;<volume>396</volume>(<issue>10248</issue>):<fpage>413</fpage>-<lpage>446</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(20)30367-6</pub-id><?supplied-pmid 32738937?><pub-id pub-id-type="pmid">32738937</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoeft</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Hinton</surname><given-names>L</given-names></string-name>, <string-name><surname>Liu</surname><given-names>J</given-names></string-name>, <string-name><surname>Unützer</surname><given-names>J</given-names></string-name></person-group>. <article-title>Directions for effectiveness research to improve health services for late-life depression in the United States</article-title>. <source>Am J Geriatr Psychiatry</source>. <year>2016</year>;<volume>24</volume>(<issue>1</issue>):<fpage>18</fpage>-<lpage>30</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jagp.2015.07.003</pub-id><?supplied-pmid 26525996?><pub-id pub-id-type="pmid">26525996</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>McClintock</surname><given-names>SM</given-names></string-name>, <string-name><surname>Reti</surname><given-names>IM</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>LL</given-names></string-name>, <etal/>; <collab>National Network of Depression Centers rTMS Task Group</collab>; <collab>American Psychiatric Association Council on Research Task Force on Novel Biomarkers and Treatments</collab></person-group>. <article-title>Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression</article-title>. <source>J Clin Psychiatry</source>. <year>2018</year>;<volume>79</volume>(<issue>1</issue>):<elocation-id>16cs10905</elocation-id>. doi:<pub-id pub-id-type="doi">10.4088/JCP.16cs10905</pub-id><?supplied-pmid 28541649?><pub-id pub-id-type="pmid">28541649</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cappon</surname><given-names>D</given-names></string-name>, <string-name><surname>den Boer</surname><given-names>T</given-names></string-name>, <string-name><surname>Jordan</surname><given-names>C</given-names></string-name>, <string-name><surname>Yu</surname><given-names>W</given-names></string-name>, <string-name><surname>Metzger</surname><given-names>E</given-names></string-name>, <string-name><surname>Pascual-Leone</surname><given-names>A</given-names></string-name></person-group>. <article-title>Transcranial magnetic stimulation (TMS) for geriatric depression</article-title>. <source>Ageing Res Rev</source>. <year>2022</year>;<volume>74</volume>:<elocation-id>101531</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.arr.2021.101531</pub-id><?supplied-pmid 34839043?><pub-id pub-id-type="pmid">34839043</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Trevizol</surname><given-names>AP</given-names></string-name>, <string-name><surname>Goldberger</surname><given-names>KW</given-names></string-name>, <string-name><surname>Mulsant</surname><given-names>BH</given-names></string-name>, <etal/></person-group>. <article-title>Unilateral and bilateral repetitive transcranial magnetic stimulation for treatment-resistant late-life depression</article-title>. <source>Int J Geriatr Psychiatry</source>. <year>2019</year>;<volume>34</volume>(<issue>6</issue>):<fpage>822</fpage>-<lpage>827</lpage>. doi:<pub-id pub-id-type="doi">10.1002/gps.5091</pub-id><?supplied-pmid 30854751?><pub-id pub-id-type="pmid">30854751</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Huang</surname><given-names>YZ</given-names></string-name>, <string-name><surname>Edwards</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Rounis</surname><given-names>E</given-names></string-name>, <string-name><surname>Bhatia</surname><given-names>KP</given-names></string-name>, <string-name><surname>Rothwell</surname><given-names>JC</given-names></string-name></person-group>. <article-title>Theta burst stimulation of the human motor cortex</article-title>. <source>Neuron</source>. <year>2005</year>;<volume>45</volume>(<issue>2</issue>):<fpage>201</fpage>-<lpage>206</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.neuron.2004.12.033</pub-id><?supplied-pmid 15664172?><pub-id pub-id-type="pmid">15664172</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Blumberger</surname><given-names>DM</given-names></string-name>, <string-name><surname>Vila-Rodriguez</surname><given-names>F</given-names></string-name>, <string-name><surname>Thorpe</surname><given-names>KE</given-names></string-name>, <etal/></person-group>. <article-title>Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial</article-title>. <source>Lancet</source>. <year>2018</year>;<volume>391</volume>(<issue>10131</issue>):<fpage>1683</fpage>-<lpage>1692</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(18)30295-2</pub-id><?supplied-pmid 29726344?><pub-id pub-id-type="pmid">29726344</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Di Lazzaro</surname><given-names>V</given-names></string-name>, <string-name><surname>Dileone</surname><given-names>M</given-names></string-name>, <string-name><surname>Pilato</surname><given-names>F</given-names></string-name>, <etal/></person-group>. <article-title>Modulation of motor cortex neuronal networks by rTMS: comparison of local and remote effects of six different protocols of stimulation</article-title>. <source>J Neurophysiol</source>. <year>2011</year>;<volume>105</volume>(<issue>5</issue>):<fpage>2150</fpage>-<lpage>2156</lpage>. doi:<pub-id pub-id-type="doi">10.1152/jn.00781.2010</pub-id><?supplied-pmid 21346213?><pub-id pub-id-type="pmid">21346213</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>O’Reardon</surname><given-names>JP</given-names></string-name>, <string-name><surname>Solvason</surname><given-names>HB</given-names></string-name>, <string-name><surname>Janicak</surname><given-names>PG</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial</article-title>. <source>Biol Psychiatry</source>. <year>2007</year>;<volume>62</volume>(<issue>11</issue>):<fpage>1208</fpage>-<lpage>1216</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopsych.2007.01.018</pub-id><?supplied-pmid 17573044?><pub-id pub-id-type="pmid">17573044</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Li</surname><given-names>CT</given-names></string-name>, <string-name><surname>Chen</surname><given-names>MH</given-names></string-name>, <string-name><surname>Juan</surname><given-names>CH</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy of prefrontal theta-burst stimulation in refractory depression: a randomized sham-controlled study</article-title>. <source>Brain</source>. <year>2014</year>;<volume>137</volume>(<issue>Pt 7</issue>):<fpage>2088</fpage>-<lpage>2098</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awu109</pub-id><?supplied-pmid 24817188?><pub-id pub-id-type="pmid">24817188</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sheehan</surname><given-names>DV</given-names></string-name>, <string-name><surname>Lecrubier</surname><given-names>Y</given-names></string-name>, <string-name><surname>Sheehan</surname><given-names>KH</given-names></string-name>, <etal/></person-group>. <article-title>The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10</article-title>. <source>J Clin Psychiatry</source>. <year>1998</year>;<volume>59</volume>(<issue>suppl 20</issue>):<fpage>22</fpage>-<lpage>33</lpage>.<?supplied-pmid 9881538?><pub-id pub-id-type="pmid">9881538</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Montgomery</surname><given-names>SA</given-names></string-name>, <string-name><surname>Asberg</surname><given-names>M</given-names></string-name></person-group>. <article-title>A new depression scale designed to be sensitive to change</article-title>. <source>Br J Psychiatry</source>. <year>1979</year>;<volume>134</volume>:<fpage>382</fpage>-<lpage>389</lpage>. doi:<pub-id pub-id-type="doi">10.1192/bjp.134.4.382</pub-id><?supplied-pmid 444788?><pub-id pub-id-type="pmid">444788</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sackeim</surname><given-names>HA</given-names></string-name></person-group>. <article-title>The definition and meaning of treatment-resistant depression</article-title>. <source>J Clin Psychiatry</source>. <year>2001</year>;<volume>62</volume>(<issue>suppl 16</issue>):<fpage>10</fpage>-<lpage>17</lpage>.<?supplied-pmid 11480879?><pub-id pub-id-type="pmid">11480879</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Katzman</surname><given-names>R</given-names></string-name>, <string-name><surname>Brown</surname><given-names>T</given-names></string-name>, <string-name><surname>Fuld</surname><given-names>P</given-names></string-name>, <string-name><surname>Peck</surname><given-names>A</given-names></string-name>, <string-name><surname>Schechter</surname><given-names>R</given-names></string-name>, <string-name><surname>Schimmel</surname><given-names>H</given-names></string-name></person-group>. <article-title>Validation of a short Orientation-Memory-Concentration Test of cognitive impairment</article-title>. <source>Am J Psychiatry</source>. <year>1983</year>;<volume>140</volume>(<issue>6</issue>):<fpage>734</fpage>-<lpage>739</lpage>. doi:<pub-id pub-id-type="doi">10.1176/ajp.140.6.734</pub-id><?supplied-pmid 6846631?><pub-id pub-id-type="pmid">6846631</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Fox</surname><given-names>MD</given-names></string-name>, <string-name><surname>Buckner</surname><given-names>RL</given-names></string-name>, <string-name><surname>White</surname><given-names>MP</given-names></string-name>, <string-name><surname>Greicius</surname><given-names>MD</given-names></string-name>, <string-name><surname>Pascual-Leone</surname><given-names>A</given-names></string-name></person-group>. <article-title>Efficacy of transcranial magnetic stimulation targets for depression is related to intrinsic functional connectivity with the subgenual cingulate</article-title>. <source>Biol Psychiatry</source>. <year>2012</year>;<volume>72</volume>(<issue>7</issue>):<fpage>595</fpage>-<lpage>603</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.biopsych.2012.04.028</pub-id><?supplied-pmid 22658708?><pub-id pub-id-type="pmid">22658708</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mir-Moghtadaei</surname><given-names>A</given-names></string-name>, <string-name><surname>Caballero</surname><given-names>R</given-names></string-name>, <string-name><surname>Fried</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Concordance between BeamF3 and MRI-neuronavigated target sites for repetitive transcranial magnetic stimulation of the left dorsolateral prefrontal cortex</article-title>. <source>Brain Stimul</source>. <year>2015</year>;<volume>8</volume>(<issue>5</issue>):<fpage>965</fpage>-<lpage>973</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brs.2015.05.008</pub-id><?supplied-pmid 26115776?><pub-id pub-id-type="pmid">26115776</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hamilton</surname><given-names>M</given-names></string-name></person-group>. <article-title>Development of a rating scale for primary depressive illness</article-title>. <source>Br J Soc Clin Psychol</source>. <year>1967</year>;<volume>6</volume>(<issue>4</issue>):<fpage>278</fpage>-<lpage>296</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.2044-8260.1967.tb00530.x</pub-id><?supplied-pmid 6080235?><pub-id pub-id-type="pmid">6080235</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Rush</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Trivedi</surname><given-names>MH</given-names></string-name>, <string-name><surname>Ibrahim</surname><given-names>HM</given-names></string-name>, <etal/></person-group>. <article-title>The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression</article-title>. <source>Biol Psychiatry</source>. <year>2003</year>;<volume>54</volume>(<issue>5</issue>):<fpage>573</fpage>-<lpage>583</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0006-3223(02)01866-8</pub-id><?supplied-pmid 12946886?><pub-id pub-id-type="pmid">12946886</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Derogatis</surname><given-names>LR</given-names></string-name>, <string-name><surname>Melisaratos</surname><given-names>N</given-names></string-name></person-group>. <article-title>The Brief Symptom Inventory: an introductory report</article-title>. <source>Psychol Med</source>. <year>1983</year>;<volume>13</volume>(<issue>3</issue>):<fpage>595</fpage>-<lpage>605</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0033291700048017</pub-id><?supplied-pmid 6622612?><pub-id pub-id-type="pmid">6622612</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Miller</surname><given-names>MD</given-names></string-name>, <string-name><surname>Paradis</surname><given-names>CF</given-names></string-name>, <string-name><surname>Houck</surname><given-names>PR</given-names></string-name>, <etal/></person-group>. <article-title>Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale</article-title>. <source>Psychiatry Res</source>. <year>1992</year>;<volume>41</volume>(<issue>3</issue>):<fpage>237</fpage>-<lpage>248</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0165-1781(92)90005-N</pub-id><?supplied-pmid 1594710?><pub-id pub-id-type="pmid">1594710</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Butters</surname><given-names>MA</given-names></string-name>, <string-name><surname>Whyte</surname><given-names>EM</given-names></string-name>, <string-name><surname>Nebes</surname><given-names>RD</given-names></string-name>, <etal/></person-group>. <article-title>The nature and determinants of neuropsychological functioning in late-life depression</article-title>. <source>Arch Gen Psychiatry</source>. <year>2004</year>;<volume>61</volume>(<issue>6</issue>):<fpage>587</fpage>-<lpage>595</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archpsyc.61.6.587</pub-id><?supplied-pmid 15184238?><pub-id pub-id-type="pmid">15184238</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Butters</surname><given-names>MA</given-names></string-name>, <string-name><surname>Bhalla</surname><given-names>RK</given-names></string-name>, <string-name><surname>Mulsant</surname><given-names>BH</given-names></string-name>, <etal/></person-group>. <article-title>Executive functioning, illness course, and relapse/recurrence in continuation and maintenance treatment of late-life depression: is there a relationship?</article-title><source>Am J Geriatr Psychiatry</source>. <year>2004</year>;<volume>12</volume>(<issue>4</issue>):<fpage>387</fpage>-<lpage>394</lpage>. doi:<pub-id pub-id-type="doi">10.1176/appi.ajgp.12.4.387</pub-id><?supplied-pmid 15249276?><pub-id pub-id-type="pmid">15249276</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Delis</surname><given-names>DC</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>JH</given-names></string-name>, <string-name><surname>Kaplan</surname><given-names>E</given-names></string-name>, <string-name><surname>Holdnack</surname><given-names>J</given-names></string-name></person-group>. <article-title>Reliability and validity of the Delis-Kaplan Executive Function System: an update</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2004</year>;<volume>10</volume>(<issue>2</issue>):<fpage>301</fpage>-<lpage>303</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1355617704102191</pub-id><?supplied-pmid 15012851?><pub-id pub-id-type="pmid">15012851</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Weintraub</surname><given-names>S</given-names></string-name>, <string-name><surname>Dikmen</surname><given-names>SS</given-names></string-name>, <string-name><surname>Heaton</surname><given-names>RK</given-names></string-name>, <etal/></person-group>. <article-title>The cognition battery of the NIH toolbox for assessment of neurological and behavioral function: validation in an adult sample</article-title>. <source>J Int Neuropsychol Soc</source>. <year>2014</year>;<volume>20</volume>(<issue>6</issue>):<fpage>567</fpage>-<lpage>578</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S1355617714000320</pub-id><?supplied-pmid 24959840?><pub-id pub-id-type="pmid">24959840</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r27">
                <label>27</label>
                <mixed-citation publication-type="book"><person-group><string-name><surname>Delis</surname><given-names>DC</given-names></string-name>, <string-name><surname>Kramer</surname><given-names>JH</given-names></string-name>, <string-name><surname>Kaplan</surname><given-names>E</given-names></string-name>, <string-name><surname>Ober</surname><given-names>BA</given-names></string-name></person-group>. <source>California Verbal Learning Test—Second Edition, Adult Version</source>. APA PsycTests; <year>2000</year>.</mixed-citation>
              </ref>
              <ref id="yoi220060r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nasreddine</surname><given-names>ZS</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>NA</given-names></string-name>, <string-name><surname>Bédirian</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment</article-title>. <source>J Am Geriatr Soc</source>. <year>2005</year>;<volume>53</volume>(<issue>4</issue>):<fpage>695</fpage>-<lpage>699</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1532-5415.2005.53221.x</pub-id><?supplied-pmid 15817019?><pub-id pub-id-type="pmid">15817019</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r29">
                <label>29</label>
                <mixed-citation publication-type="book"><person-group><collab>National Collaborating Centre for Mental Health</collab></person-group>. <source>Depression in adults with a chronic physical health problem: treatment and management</source>. British Psychological Society and the Royal College of Psychiatrists; <year>2010</year>.</mixed-citation>
              </ref>
              <ref id="yoi220060r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mauri</surname><given-names>L</given-names></string-name>, <string-name><surname>D’Agostino</surname><given-names>RB</given-names><suffix>Sr</suffix></string-name></person-group>. <article-title>Challenges in the design and interpretation of noninferiority trials</article-title>. <source>N Engl J Med</source>. <year>2017</year>;<volume>377</volume>(<issue>14</issue>):<fpage>1357</fpage>-<lpage>1367</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMra1510063</pub-id><?supplied-pmid 28976859?><pub-id pub-id-type="pmid">28976859</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Gaynes</surname><given-names>BN</given-names></string-name>, <string-name><surname>Lloyd</surname><given-names>SW</given-names></string-name>, <string-name><surname>Lux</surname><given-names>L</given-names></string-name>, <etal/></person-group>. <article-title>Repetitive transcranial magnetic stimulation for treatment-resistant depression: a systematic review and meta-analysis</article-title>. <source>J Clin Psychiatry</source>. <year>2014</year>;<volume>75</volume>(<issue>5</issue>):<fpage>477</fpage>-<lpage>489</lpage>. doi:<pub-id pub-id-type="doi">10.4088/JCP.13r08815</pub-id><?supplied-pmid 24922485?><pub-id pub-id-type="pmid">24922485</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaster</surname><given-names>TS</given-names></string-name>, <string-name><surname>Daskalakis</surname><given-names>ZJ</given-names></string-name>, <string-name><surname>Noda</surname><given-names>Y</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy, tolerability, and cognitive effects of deep transcranial magnetic stimulation for late-life depression: a prospective randomized controlled trial</article-title>. <source>Neuropsychopharmacology</source>. <year>2018</year>;<volume>43</volume>(<issue>11</issue>):<fpage>2231</fpage>-<lpage>2238</lpage>.<pub-id pub-id-type="pmid">29946106</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lenze</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Mulsant</surname><given-names>BH</given-names></string-name>, <string-name><surname>Blumberger</surname><given-names>DM</given-names></string-name>, <etal/></person-group>. <article-title>Efficacy, safety, and tolerability of augmentation pharmacotherapy with aripiprazole for treatment-resistant depression in late life: a randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>10011</issue>):<fpage>2404</fpage>-<lpage>2412</lpage>. doi:<pub-id pub-id-type="doi">10.1016/S0140-6736(15)00308-6</pub-id><?supplied-pmid 26423182?><pub-id pub-id-type="pmid">26423182</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Brunoni</surname><given-names>AR</given-names></string-name>, <string-name><surname>Chaimani</surname><given-names>A</given-names></string-name>, <string-name><surname>Moffa</surname><given-names>AH</given-names></string-name>, <etal/></person-group>. <article-title>Repetitive transcranial magnetic stimulation for the acute treatment of major depressive episodes: a systematic review with network meta-analysis</article-title>. <source>JAMA Psychiatry</source>. <year>2017</year>;<volume>74</volume>(<issue>2</issue>):<fpage>143</fpage>-<lpage>152</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapsychiatry.2016.3644</pub-id><?supplied-pmid 28030740?><pub-id pub-id-type="pmid">28030740</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mutz</surname><given-names>J</given-names></string-name>, <string-name><surname>Vipulananthan</surname><given-names>V</given-names></string-name>, <string-name><surname>Carter</surname><given-names>B</given-names></string-name>, <string-name><surname>Hurlemann</surname><given-names>R</given-names></string-name>, <string-name><surname>Fu</surname><given-names>CHY</given-names></string-name>, <string-name><surname>Young</surname><given-names>AH</given-names></string-name></person-group>. <article-title>Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis</article-title>. <source>BMJ</source>. <year>2019</year>;<volume>364</volume>:<fpage>l1079</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.l1079</pub-id><?supplied-pmid 30917990?><pub-id pub-id-type="pmid">30917990</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Li</surname><given-names>CT</given-names></string-name>, <string-name><surname>Chen</surname><given-names>MH</given-names></string-name>, <string-name><surname>Juan</surname><given-names>CH</given-names></string-name>, <etal/></person-group>. <article-title>Effects of prefrontal theta-burst stimulation on brain function in treatment-resistant depression: a randomized sham-controlled neuroimaging study</article-title>. <source>Brain Stimul</source>. <year>2018</year>;<volume>11</volume>(<issue>5</issue>):<fpage>1054</fpage>-<lpage>1062</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brs.2018.04.014</pub-id><?supplied-pmid 29730251?><pub-id pub-id-type="pmid">29730251</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Aaronson</surname><given-names>ST</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>LL</given-names></string-name>, <string-name><surname>Hutton</surname><given-names>TM</given-names></string-name>, <etal/></person-group>. <article-title>Comparison of clinical outcomes with left unilateral and sequential bilateral transcranial magnetic stimulation (TMS) treatment of major depressive disorder in a large patient registry</article-title>. <source>Brain Stimul</source>. <year>2022</year>;<volume>15</volume>(<issue>2</issue>):<fpage>326</fpage>-<lpage>336</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brs.2022.01.006</pub-id><?supplied-pmid 35074549?><pub-id pub-id-type="pmid">35074549</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Everson-Stewart</surname><given-names>S</given-names></string-name>, <string-name><surname>Emerson</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Bio-creep in non-inferiority clinical trials</article-title>. <source>Stat Med</source>. <year>2010</year>;<volume>29</volume>(<issue>27</issue>):<fpage>2769</fpage>-<lpage>2780</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.4053</pub-id><?supplied-pmid 20809482?><pub-id pub-id-type="pmid">20809482</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nahas</surname><given-names>Z</given-names></string-name>, <string-name><surname>Li</surname><given-names>X</given-names></string-name>, <string-name><surname>Kozel</surname><given-names>FA</given-names></string-name>, <etal/></person-group>. <article-title>Safety and benefits of distance-adjusted prefrontal transcranial magnetic stimulation in depressed patients 55-75 years of age: a pilot study</article-title>. <source>Depress Anxiety</source>. <year>2004</year>;<volume>19</volume>(<issue>4</issue>):<fpage>249</fpage>-<lpage>256</lpage>. doi:<pub-id pub-id-type="doi">10.1002/da.20015</pub-id><?supplied-pmid 15274174?><pub-id pub-id-type="pmid">15274174</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Chen</surname><given-names>L</given-names></string-name>, <string-name><surname>Thomas</surname><given-names>EHX</given-names></string-name>, <string-name><surname>Kaewpijit</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>Accelerated theta burst stimulation for the treatment of depression: a randomised controlled trial</article-title>. <source>Brain Stimul</source>. <year>2021</year>;<volume>14</volume>(<issue>5</issue>):<fpage>1095</fpage>-<lpage>1105</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.brs.2021.07.018</pub-id><?supplied-pmid 34332155?><pub-id pub-id-type="pmid">34332155</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sackeim</surname><given-names>HA</given-names></string-name>, <string-name><surname>Aaronson</surname><given-names>ST</given-names></string-name>, <string-name><surname>Carpenter</surname><given-names>LL</given-names></string-name>, <etal/></person-group>. <article-title>Clinical outcomes in a large registry of patients with major depressive disorder treated with transcranial magnetic stimulation</article-title>. <source>J Affect Disord</source>. <year>2020</year>;<volume>277</volume>:<fpage>65</fpage>-<lpage>74</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jad.2020.08.005</pub-id><?supplied-pmid 32799106?><pub-id pub-id-type="pmid">32799106</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Cole</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Phillips</surname><given-names>AL</given-names></string-name>, <string-name><surname>Bentzley</surname><given-names>BS</given-names></string-name>, <etal/></person-group>. <article-title>Stanford neuromodulation therapy (SNT): a double-blind randomized controlled trial</article-title>. <source>Am J Psychiatry</source>. <year>2022</year>;<volume>179</volume>(<issue>2</issue>):<fpage>132</fpage>-<lpage>141</lpage>.<?supplied-pmid 34711062?><pub-id pub-id-type="pmid">34711062</pub-id></mixed-citation>
              </ref>
              <ref id="yoi220060r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Trevizol</surname><given-names>AP</given-names></string-name>, <string-name><surname>Downar</surname><given-names>J</given-names></string-name>, <string-name><surname>Vila-Rodriguez</surname><given-names>F</given-names></string-name>, <string-name><surname>Thorpe</surname><given-names>KE</given-names></string-name>, <string-name><surname>Daskalakis</surname><given-names>ZJ</given-names></string-name>, <string-name><surname>Blumberger</surname><given-names>DM</given-names></string-name></person-group>. <article-title>Predictors of remission after repetitive transcranial magnetic stimulation for the treatment of major depressive disorder: an analysis from the randomised non-inferiority THREE-D trial</article-title>. <source>EClinicalMedicine</source>. <year>2020</year>;<volume>22</volume>:<elocation-id>100349</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.eclinm.2020.100349</pub-id><?supplied-pmid 32382720?><pub-id pub-id-type="pmid">32382720</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-YOI220060-1">
              <supplementary-material id="note-YOI220060-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>Trial protocol</p>
                </caption>
                <media xlink:href="jamapsychiatry-e222862-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p>eTable 1. Linear Mixed-Effect Model Analysis for Depression Severity Scores from Baseline to Final Treatment and Follow-Up</p>
                  <p>eTable 2. Response, Remission and Change in Depression Severity Scores from Baseline to Final Treatment with 95% CI</p>
                  <p>eTable 3. Linear Mixed-Effect Model of Cognitive Outcomes from Baselines, Final and 12-Week Post Treatment </p>
                </caption>
                <media xlink:href="jamapsychiatry-e222862-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>Data sharing statement</p>
                </caption>
                <media xlink:href="jamapsychiatry-e222862-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
